Literature DB >> 25711241

Anaphylaxis and cardiovascular disease: therapeutic dilemmas.

P Lieberman1, F E R Simons2.   

Abstract

Cardiovascular disease (CVD) increases the risk of severe or fatal anaphylaxis, and some medications for CVD treatment can exacerbate anaphylaxis. The aim of this article is to review the effect of anaphylaxis on the heart, the potential impact of medications for CVD on anaphylaxis and anaphylaxis treatment, and the cardiovascular effects of epinephrine. The therapeutic dilemmas arising from these issues are also discussed and management strategies proposed. PubMed searches were performed for the years 1990-2014 inclusive, using terms such as angiotensin-converting enzyme (ACE) inhibitors, adrenaline, allergic myocardial infarction, anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis syndrome. Literature analysis indicated that: cardiac mast cells are key constituents of atherosclerotic plaques; mast cell mediators play an important role in acute coronary syndrome (ACS); patients with CVD are at increased risk of developing severe or fatal anaphylaxis; and medications for CVD treatment, including beta-adrenergic blockers and ACE inhibitors, potentially exacerbate anaphylaxis or make it more difficult to treat. Epinephrine increases myocardial contractility, decreases the duration of systole relative to diastole, and enhances coronary blood flow. Its transient adverse effects include pallor, tremor, anxiety, and palpitations. Serious adverse effects (including ventricular arrhythmias and hypertension) are rare, and are significantly more likely after intravenous injection than after intramuscular injection. Epinephrine is life-saving in anaphylaxis; second-line medications (including antihistamines and glucocorticoids) are not. In CVD patients (especially those with ACS), the decision to administer epinephrine for anaphylaxis can be difficult, and its benefits and potential harms need to be carefully considered. Concerns about potential adverse effects need to be weighed against concerns about possible death from untreated anaphylaxis, but there is no absolute contraindication to epinephrine injection in anaphylaxis.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25711241     DOI: 10.1111/cea.12520

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  18 in total

1.  Kounis syndrome and systemic mastocytosis in a 52-year-old man having surgery.

Authors:  Marina Lerner; Raveen S Pal; Rozita Borici-Mazi
Journal:  CMAJ       Date:  2016-08-02       Impact factor: 8.262

2.  Anaphylaxis in older adult patients: a 10-year retrospective experience.

Authors:  Eray Yıldız; Şevket Arslan; Fatih Çölkesen; Recep Evcen; Filiz Sadi Aykan; Mehmet Kılınç
Journal:  World Allergy Organ J       Date:  2022-07-14       Impact factor: 5.516

Review 3.  Cutaneous Drug Reactions in the Elderly.

Authors:  James W S Young; Neil H Shear
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 4.271

Review 4.  How to manage anaphylaxis in primary care.

Authors:  Alberto Alvarez-Perea; Luciana Kase Tanno; María L Baeza
Journal:  Clin Transl Allergy       Date:  2017-12-11       Impact factor: 5.871

5.  Acute myocardial injury after administration of intravenous epinephrine for allergic reaction.

Authors:  Katerina Zakka; Sneha Gadi; Nikoloz Koshlelashvili; Noble M Maleque
Journal:  SAGE Open Med Case Rep       Date:  2020-06-17

Review 6.  Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.

Authors:  Teodorikez Wilfox Jimenez-Rodriguez; Marlene Garcia-Neuer; Leila A Alenazy; Mariana Castells
Journal:  J Asthma Allergy       Date:  2018-06-20

7.  Anaphylaxis cases presenting to primary care paramedics in Quebec.

Authors:  Nofar Kimchi; Ann Clarke; Jocelyn Moisan; Colette Lachaine; Sebastien La Vieille; Yuka Asai; Lawrence Joseph; Chris Mill; Moshe Ben-Shoshan
Journal:  Immun Inflamm Dis       Date:  2015-08-16

8.  2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.

Authors:  F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh
Journal:  World Allergy Organ J       Date:  2015-10-28       Impact factor: 4.084

Review 9.  Fatal Anaphylaxis: Mortality Rate and Risk Factors.

Authors:  Paul J Turner; Elina Jerschow; Thisanayagam Umasunthar; Robert Lin; Dianne E Campbell; Robert J Boyle
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Sep - Oct

10.  Endothelial Regulator of Calcineurin 1 Promotes Barrier Integrity and Modulates Histamine-Induced Barrier Dysfunction in Anaphylaxis.

Authors:  Constanza Ballesteros-Martinez; Nerea Mendez-Barbero; Alma Montalvo-Yuste; Bettina M Jensen; Aída Gomez-Cardenosa; Lotte Klitfod; María Garrido-Arandia; Gloria Alvarez-Llamas; Carlos Pastor-Vargas; Fernando Vivanco; Lene Heise Garvey; Javier Cuesta-Herranz; Lars K Poulsen; Vanesa Esteban
Journal:  Front Immunol       Date:  2017-10-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.